Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06034275 |
Recruitment Status :
Recruiting
First Posted : September 13, 2023
Last Update Posted : January 12, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Myeloid Leukemia B-cell Acute Lymphoblastic Leukemia High-risk Myelodysplastic Syndrome | Drug: VIP943 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 36 participants |
Allocation: | N/A |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies |
Actual Study Start Date : | September 13, 2023 |
Estimated Primary Completion Date : | May 30, 2025 |
Estimated Study Completion Date : | December 31, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Dose Escalation of VIP943
Subjects with AML, MDS, and B-ALL with CD123 expression will be administered VIP 943 in sequential ascending doses as a monotherapy via intravenous (IV) administration weekly (QW).
|
Drug: VIP943
VIP943 will be administered by IV Infusion weekly |
- Incidence of DLT (Dose limit toxicity) of VIP943 [ Time Frame: Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 28 days ]
- Response rate to VIP943 as assessed by investigators using disease-specific response criteria [ Time Frame: Cycle 1 Day 1 up to 30 days after the last dose, where each cycle is up to 28 days (up to approximately 10 months) ]
- Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of VIP943 [ Time Frame: Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 28 days ]
- Area under the concentration versus time curve from zero to infinity after single (first) dose (AUC) of VIP943 [ Time Frame: Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 28 days ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically confirmed AML, B-ALL or MDS. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies.
- Evidence of ≥5% bone marrow or blood blasts (acute leukemia) or ≥5% bone marrow or blood myeloblasts (MDS) to allow for assessment of drug activity.
- Evidence of CD123 expression from a local laboratory.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Exclusion Criteria:
- Known central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Clinically significant cardiac disease including congestive heart failure > New York Heart Association (NYHA) Class II), evidence for coronary artery disease (eg, unstable angina (anginal symptoms at rest) or new-onset angina (within the last 6 months or myocardial infarction within the past 6 months before first dose.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06034275
Contact: Vincerx Clinical Trials Contact | 16508006676 | clinicaltrials@vincerx.com |
United States, Alabama | |
University of Alabama at Birmingham | Recruiting |
Birmingham, Alabama, United States, 35233 | |
Contact: Research Site | |
United States, Ohio | |
University of Cincinnati | Recruiting |
Cincinnati, Ohio, United States, 45219 | |
Contact: Research Site | |
United States, Tennessee | |
TriStar Bone Marrow Transplant | Recruiting |
Nashville, Tennessee, United States, 37203 | |
Contact: Research Site | |
United States, Texas | |
MD Anderson Cancer Center | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Research Site |
Study Director: | Vincerx Study Director | Vincerx Pharma, Inc. |
Responsible Party: | Vincerx Pharma, Inc. |
ClinicalTrials.gov Identifier: | NCT06034275 |
Other Study ID Numbers: |
VNC-943-101 |
First Posted: | September 13, 2023 Key Record Dates |
Last Update Posted: | January 12, 2024 |
Last Verified: | January 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
ADC Hematologic Malignancies Leukemia CD123 B-ALL |
AML MDS Relapsed/ Refractory Hematologic Diseases Bone Marrow Diseases |
Leukemia Neoplasms Precursor Cell Lymphoblastic Leukemia-Lymphoma Hematologic Neoplasms Myelodysplastic Syndromes Neoplasms by Histologic Type Hematologic Diseases |
Bone Marrow Diseases Leukemia, Lymphoid Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Neoplasms by Site |